Cargando…
Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance mutations in the clinic. We believe that this is du...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189025/ https://www.ncbi.nlm.nih.gov/pubmed/25166745 http://dx.doi.org/10.3390/v6093377 |